Barclays
SLDB icon

Barclays’s Solid Biosciences SLDB Stock Holding History

Barclays’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-667
Closed -$45K – 6429
2019
Q4 		$45K Sell
667
-7,760
-92% -$856K ﹤0.01% 5765
2019
Q3 		$1.31M Sell
8,427
-5,666
-40% -$641K ﹤0.01% 3390
2019
Q2 		$1.22M Buy
+14,093
New +$1.54M ﹤0.01% 3482

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's SLDB Position: Q2 2026 in Review

Barclays increased its Solid Biosciences (SLDB) stake by 10% in Q2 2026, buying an estimated $46.4K and bringing the position to 65,003 shares worth $649K. The position accounts for ﹤0.01% of the portfolio, ranked #3063.

Barclays first reported a position in SLDB in Q1 2018 and has held it in 34 quarters since. The position peaked at $3.94M in Q1 2019. 156 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Barclays held 65,003 shares of Solid Biosciences worth $649K as of Q2 2026.
  • Barclays bought 6,126 Solid Biosciences shares in Q2 2026, an estimated $46.4K.
  • Solid Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3063 holding.
  • Barclays first reported a position in Solid Biosciences in Q1 2018 and has held it in 34 quarters since.
  • Barclays's Solid Biosciences position peaked at $3.94M in Q1 2019.
  • 156 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.